Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305256 | 0.88 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL2493322 | 0.85 | PPARG (0.40) | SMN1; SMN2LMNAMEN1KMT2ALDHA | |
| SCHEMBL2494917 | 0.85 | PTGS2 (0.51) | SMN1; SMN2LDHAKDM4EPPARGALDH1A1 | |
| SCHEMBL10305237 | 0.77 | ALDH1A1 (0.36) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1565617 | 0.76 | LDHA (0.63) | SMN1; SMN2LMNAMEN1KMT2ALDHA | |
| SCHEMBL2494857 | 0.75 | PPARG (0.51) | SMN1; SMN2LMNAPPARGPTGESALOX5 | |
| SCHEMBL10305254 | 0.75 | PTGS2 (0.43) | LMNAMEN1KMT2AKDM4EPPARG | |
| SCHEMBL1566439 | 0.74 | LDHA (0.55) | SMN1; SMN2MEN1KMT2ALDHAKDM4E | |
| SCHEMBL2495693 | 0.73 | PPARG (0.52) | MEN1KMT2APPARG | |
| SCHEMBL1565656 | 0.73 | LDHA (0.54) | SMN1; SMN2LMNALDHAKDM4EPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1751127-A2 | NOVEL CYLOPENTA¬B|BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113529-A2 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | BAYER HEALTHCARE AG (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | FKBP1A, FKBP2, FKBP1B | SMN1; SMN2 4246/4885LMNA 1774/4885MEN1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.